



Redsense receives SEK 500,000 in funding from Vinnova to develop AI-driven wound monitoring software

Redsense Medical AB has received a grant of SEK 500,000 from Vinnova, Sweden's government agency for innovation, to carry out an innovation project in artificial intelligence. The aim of the project is to develop an AI-driven software, which will be employed in a smart monitoring system for wound care. The grant is awarded as part of the agency's new effort "Start your AI journey", with the overall goal of advancing Sweden's position within AI and machine learning.

Redsense is a medical device company that provides an innovative system to detect blood loss during hemodialysis by means of patented fibre optic sensors. It is the company's long-term strategy to expand the use of this technology to new areas, including chronic wound care. As part of this effort, Redsense is now developing a smart wound monitoring system that will measure the physiological parameters relevant to the healing process in real time. The system consists of a disposable and safe sensor layer, low-cost and easily integrated into existing wound dressings, which will be controlled by a microprocessor.

The company will utilize the grant to develop a software module, where sensor data will be processed with the use of AI/ML algorithms. An existing set of simulation data from 400,000 dialysis treatments monitored for blood loss with Redsense's technology will be used to train the algorithms.

"We see machine learning as the most convenient approach to distinguish meaningful information from noise in the signal, and to establish which parameters are the most relevant; it is also much more cost-efficient in comparison with building a set of expert rules," says Patrik Byhmer, CEO of Redsense Medical AB.

At the conclusion of the project, the company expects to have developed a proof of concept (PoC) software to control the sensors, and also to have gained valuable indications on the optimal design of the sensor itself.

"A successful PoC will give us the opportunity to move things one step further. This innovation will target the fast growing market of advanced wound care products. It will also be a game changer for chronic wound patients and healthcare professionals, as it will enable early detection of possible complications, reduce pain and discomfort and provide faster and personalized healing," says Patrik Byhmer.

For more information, please contact:

Patrik Byhmer, CEO Redsense Medical AB (publ)

Phone: +46 35 10 60 30

info@redsensemecal.com

www.redsensemecal.com

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.